MX351779B - Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens). - Google Patents

Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).

Info

Publication number
MX351779B
MX351779B MX2013010035A MX2013010035A MX351779B MX 351779 B MX351779 B MX 351779B MX 2013010035 A MX2013010035 A MX 2013010035A MX 2013010035 A MX2013010035 A MX 2013010035A MX 351779 B MX351779 B MX 351779B
Authority
MX
Mexico
Prior art keywords
gep
nens
predicting
gastroenteropancreatic neuroendocrine
neuroendocrine neoplasms
Prior art date
Application number
MX2013010035A
Other languages
English (en)
Other versions
MX2013010035A (es
Inventor
M Modlin Irvin
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of MX2013010035A publication Critical patent/MX2013010035A/es
Publication of MX351779B publication Critical patent/MX351779B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a biomarcadores de neoplasmas neuroendocrinos gastroentero-pancreáticos (GEP-NEN) y agentes, sistemas y equipos para detectar los mismos, y métodos de diagnóstico, de pronóstico y predictivos de GEP-NEN asociados y sus usos, tal como detección, predicción, presentación en etapas, perfilado, clasificación, y la eficacia de tratamiento del monitoreo y otros efectos.
MX2013010035A 2011-03-01 2012-03-01 Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens). MX351779B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161448137P 2011-03-01 2011-03-01
PCT/US2012/027351 WO2012119013A1 (en) 2011-03-01 2012-03-01 PREDICTING GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS (GEP-NENs)

Publications (2)

Publication Number Publication Date
MX2013010035A MX2013010035A (es) 2014-08-27
MX351779B true MX351779B (es) 2017-10-27

Family

ID=45852725

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013010035A MX351779B (es) 2011-03-01 2012-03-01 Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).

Country Status (14)

Country Link
US (1) US9988684B2 (es)
EP (1) EP2681333B1 (es)
JP (2) JP6159662B2 (es)
KR (2) KR102114412B1 (es)
CN (1) CN103502473B (es)
AU (2) AU2012223288B2 (es)
CA (1) CA2828878C (es)
DK (1) DK2681333T3 (es)
ES (1) ES2656487T3 (es)
IL (1) IL228224A (es)
MX (1) MX351779B (es)
PL (1) PL2681333T3 (es)
WO (1) WO2012119013A1 (es)
ZA (1) ZA201306686B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2907062B1 (en) 2012-10-09 2020-05-27 Five3 Genomics, LLC Method for tumor clonality analysis
CN107208132A (zh) 2014-09-15 2017-09-26 克里夫顿生命科学有限责任公司 用于诊断胃肠胰神经内分泌瘤的组合物、方法和试剂盒
CN107194137B (zh) * 2016-01-31 2023-05-23 北京万灵盘古科技有限公司 一种基于医疗数据建模的坏死性小肠结肠炎分类预测方法
CN105938521A (zh) * 2016-07-04 2016-09-14 苏州大学附属儿童医院 一种强直性脊柱炎预警模型建立方法及装置
WO2018160925A1 (en) * 2017-03-02 2018-09-07 President And Fellows Of Harvard College Methods and systems for predicting treatment responses in subjects
WO2018214249A1 (zh) * 2017-05-22 2018-11-29 立森印迹诊断技术（无锡）有限公司 一种印记基因分级模型及其组成的系统和应用
KR20200092382A (ko) 2017-11-30 2020-08-03 리퀴드 바이옵시 리서치 엘엘씨 유전자 발현 검정을 이용한 펩티드 수용체 방사선요법의 예측
CN108048564B (zh) * 2018-02-09 2021-03-05 中国科学院昆明动物研究所 人glt8d1基因的新用途
JP7061768B2 (ja) * 2018-03-09 2022-05-02 国立大学法人 東京大学 生物応答の解析方法、解析プログラム、及び解析装置
CA3003032A1 (en) * 2018-04-27 2019-10-27 Nanostics Inc. Methods of diagnosing disease using microflow cytometry
WO2019226035A1 (ko) * 2018-05-25 2019-11-28 주식회사 엠디헬스케어 Qpcr 분석을 통한 대장암 진단방법
KR102141246B1 (ko) * 2018-05-25 2020-08-04 주식회사 엠디헬스케어 qPCR 분석을 통한 대장암 진단방법
JP7133411B2 (ja) 2018-09-19 2022-09-08 テルモ株式会社 Ｃｔｃ採取システム及びｃｔｃ採取システムの作動方法
CN109190713A (zh) * 2018-09-29 2019-01-11 王海燕 基于血清质谱自适应稀疏特征选择的卵巢癌微创快检技术
US11875903B2 (en) 2018-12-31 2024-01-16 Tempus Labs, Inc. Method and process for predicting and analyzing patient cohort response, progression, and survival
EP3906564A4 (en) * 2018-12-31 2022-09-07 Tempus Labs, Inc. METHOD AND APPARATUS FOR PREDICTION AND ANALYSIS OF PATIENT COHORT RESPONSE, PROGRESSION AND SURVIVAL
CN109652550B (zh) * 2019-01-21 2022-08-02 首都医科大学附属北京朝阳医院 circ-HUWE1作为胃癌和结直肠癌诊断生物标志物和治疗靶点的应用
CN109949268A (zh) * 2019-01-24 2019-06-28 郑州大学第一附属医院 一种基于机器学习的肝细胞癌分化水平分级方法
US11995127B2 (en) * 2019-04-02 2024-05-28 Aspentech Corporation Validation of operating plans and schedules using machine learning
EP4041886A1 (en) 2019-10-10 2022-08-17 Liquid Biopsy Research LLC Compositions, methods and kits for biological sample and rna stabilization
US20230272390A1 (en) * 2020-07-29 2023-08-31 The Children's Hospital Of Philadelphia Compositions and methods for hemoglobin production
KR102438608B1 (ko) * 2021-06-15 2022-08-31 재단법인 아산사회복지재단 췌장 신경내분비 종양 감별진단용 바이오마커 조성물 및 이를 이용한 췌장 신경내분비 종양 감별진단에 필요한 정보를 제공하는 방법
KR102519913B1 (ko) * 2021-06-15 2023-04-10 재단법인 아산사회복지재단 췌장 신경내분비 종양 진단용 바이오마커 조성물 및 이를 이용한 췌장 신경내분비 종양 진단에 필요한 정보를 제공하는 방법
CN113637750A (zh) * 2021-07-16 2021-11-12 宁波市第一医院 急性髓系白血病的辅助诊断、预后诊断或危险度分层标记物及其应用
WO2024073652A1 (en) * 2022-09-30 2024-04-04 Liquid Biopsy Research LLC Methods for neuroendocrine cancer detection in saliva

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
WO2005020795A2 (en) * 2003-08-25 2005-03-10 The Johns Hopkins University Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis

Also Published As

Publication number Publication date
ZA201306686B (en) 2015-03-25
IL228224A (en) 2017-11-30
JP6321233B2 (ja) 2018-05-09
AU2017204086B2 (en) 2019-05-16
US20140066328A1 (en) 2014-03-06
DK2681333T3 (en) 2018-01-08
MX2013010035A (es) 2014-08-27
JP6159662B2 (ja) 2017-07-05
KR20140042793A (ko) 2014-04-07
IL228224A0 (en) 2013-12-31
KR102114412B1 (ko) 2020-06-18
JP2017104116A (ja) 2017-06-15
CN103502473A (zh) 2014-01-08
JP2014512172A (ja) 2014-05-22
CA2828878A1 (en) 2012-09-07
AU2012223288A1 (en) 2013-09-19
AU2017204086A1 (en) 2017-07-06
KR20180116483A (ko) 2018-10-24
PL2681333T3 (pl) 2018-03-30
ES2656487T3 (es) 2018-02-27
EP2681333B1 (en) 2017-11-15
US9988684B2 (en) 2018-06-05
EP2681333A1 (en) 2014-01-08
CA2828878C (en) 2020-08-25
CN103502473B (zh) 2016-03-09
KR102023584B1 (ko) 2019-09-24
WO2012119013A1 (en) 2012-09-07
AU2012223288B2 (en) 2017-03-30

Similar Documents

Publication Publication Date Title
MX2013010035A (es) Prediccion de neoplasmas neuroendocrinos gastroenteropancreaticos (gep-nens).
WO2013083781A3 (en) Biomarkers and test panels useful in systemic inflammatory conditions
IL254062B (en) Kits containing ptk7 antibody and their use in the treatment, detection, diagnosis or monitoring of cancer
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
MX2020004617A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
MX2015010406A (es) Metodos para predecir riesgo de neumonia intersticial.
EA201590027A1 (ru) Способы детекции заболеваний или состояний
IN2014CN04326A (es)
NZ629555A (en) Monocyte biomarkers for cancer detection
EA201390149A1 (ru) Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток
EA201290711A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
GB201316222D0 (en) Biomarker panels diagnostic and test kits for ovarian cancer
NZ606725A (en) Methods for predicting anti-cancer response
EA201500080A1 (ru) Способ in vitro диагностирования и мониторинга рака
CA2839777C (en) Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease
MX2013011334A (es) Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer.
WO2011130647A3 (en) Compositions and methods for characterizing a myopathy
WO2013044187A3 (en) Detecting ovarian cancer
WO2012139051A3 (en) Autoantibody biomarkers for iga nephropathy
GB2510539A (en) Biomarkers of cancer
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
WO2014160237A3 (en) Methods of prognosing preeclampsia
WO2014072832A8 (en) Biomarkers for cervical cancer
MX2014003137A (es) Inmunoensayo para detectar antiobioticos.
WO2014052930A3 (en) Biomarkers for prostate cancer prognosis

Legal Events

Date Code Title Description
FG Grant or registration